Jaguar Health's Crofelemer Shows Promising Results in Reducing Parenteral Nutrition

Jaguar Health, Inc., through its subsidiaries Napo Pharmaceuticals and Napo Therapeutics, reported promising proof-of-concept outcomes from their exploratory trial in Abu Dhabi. The results indicate that crofelemer, their plant-based drug, significantly decreased the need for total parenteral nutrition (TPN) in patients suffering from intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF).

The trial revealed that crofelemer reduced TPN by up to 27% in an MVID patient and 12.5% in an SBS-IF patient. Despite withdrawal after 12 weeks per protocol, patients returned to treatment due to symptom relapse. Jaguar aims to secure partnerships for developing their products, potentially leading to expedited regulatory approvals.

The study underscores crofelemer's potential in transforming treatment for conditions like MVID, an ultra-rare disease with few therapeutic solutions. Additional data presentation at global conferences may bolster its position for fast-tracked approvals in the EU and US.